Psilocybin-Research.com Searchable psychedelic science.
Loading
Psilocybin-Research.com Searchable psychedelic science.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations.

Search settings and shortcuts
Database up to date Updated Jul 4, 2026 01:22 UTC
Database 3,983 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 3,983 indexed records
3,983 Total Publications 3,842 Psilocybin Records 554 Psilocin Records 3,983 Search Matches 394 Journals 66 Research Topics
Published 3,218 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.1% Active
PubMed 303 7.6% Active
OpenAlex 288 7.2% Active
ClinicalTrials.gov 287 7.2% Active
PsyArXiv 216 5.4% Active
Crossref 159 4% Active
bioRxiv 142 3.6% Active
Publication timeline 3,080 dated records
3,080 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

3,983 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 4, 2026 01:22 UTC
Checking for newly indexed publications...
Page 32 of 200

Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex

ABSTRACT Clinical trials suggest that a single dose of psilocybin is an effective treatment for substance use disorders (SUDs). Choice impulsivity is a value-based decision-making bias that predicts drug-intake escalation and is commonly associated with SUDs. The dorsomedial prefrontal cortex (dmPFC) regulates choice impulsivity and is enriched with 5-HT2A r...

bioRxiv 2025-12-25 Houff J, Williams A, Allen O, Gisabella B, Pantazopoulos H, Del Arco A.
bioRxiv PREPRINT (not peer reviewed) psilocybin AddictionReceptor PharmacologyBiomarkersClinical Trial Clinical Trial

Psilocybin-induced modulation of visual salience processing.

Psychedelic compounds significantly reshape conscious perception, yet the implications of these alterations for complex visual-guided behaviors remain poorly understood. We investigated how psilocybin modulates visual salience processing during natural scene perception. Twenty-three participants completed eye-tracking tasks under self-blinded low and high do...

Unknown journal 2025-12-25 Muller S, Cavanna F, de la Fuente LA, Bruno N, D'Amelio TA, Pallavicini C, Tagliazucchi E.
Europe PMC Published psilocybin General Other

Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey.

Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress disorder) among neurotypical individuals, i.e., typically developing individuals without a diagnosed neurodevelopmental condition. However, their therapeutic potential for treating co-occurring mental-health conditio...

Unknown journal 2025-12-25 Afsharnia S, Liang V, Lunsky Y, Orsini AP, Tint A, Lin HY.
Europe PMC Published psilocybin DepressionPTSDClinical TrialObservational StudySafety Clinical Trial

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

BackgroundThe Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-...

Unknown journal 2025-12-25 Stocker K, Hartmann M, Schmid Y, Vogt SB, Becker AM, Ley L, Straumann I, Arikci D, Klaiber A, Erne L, Vizeli P, Holze F, Liechti ME.
Europe PMC Published psilocybin AnxietyConsciousnessHealthy Volunteers Clinical Trial

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

ClinicalTrials.gov 2025-12-23 Sheppard Pratt Health System
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionTreatment-Resistant DepressionSafety Other Treatment Resistant DepressionSuicidal Ideation

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder

The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). The primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (B...

ClinicalTrials.gov 2025-12-22 University of Chicago
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionPersonality ChangeSafety Other Borderline Personality DisorderMajor Depressive Disorder

A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants

Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study’s primary objectives examined the feasibility and safety of administering movement tasks following low-t...

medRxiv 2025-12-22 Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA.
medRxiv PREPRINT (not peer reviewed) psilocybin Headache / MigraineConsciousnessClinical TrialReview ArticleHealthy VolunteersSafetyAdverse Events Clinical Trial

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.

Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic st...

Unknown journal 2025-12-22 Liszka P, Ogórek A, Olejnik-Chlewicka KM, Puchalski K, Zasiadła M, Patrzykąt KM, Perediatkiewicz J, Urbański W, Łuczak PM, Brodowski J.
Europe PMC Published psilocybin DepressionAnxietyPTSDAddictionMechanism of ActionReceptor PharmacologyEmotional ProcessingClinical TrialReview ArticleCancer PatientsTreatment-Resistant DepressionSafetyDrug Interactions Clinical Trial

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted the...

ClinicalTrials.gov 2025-12-21 NYU Langone Health
ClinicalTrials.gov CLINICAL TRIAL psilocybin Mechanism of ActionWellbeingClinical TrialSafety Clinical Trial StutteringPsilocybin

Psilocybin modulates social behaviour in male and female mice in a time-dependent manner

With the resurgence of psychedelic research and the growing interest in their therapeutic potential, there is an urgent need to understand how these compounds act across biological sexes. Despite widespread interest in their use for conditions marked by social impairments, including depression, anxiety, and anorexia nervosa, the influence of sex as a biologi...

bioRxiv 2025-12-21 Shadani S, McCoy K, Ong L, Greaves E, Conn K, Andrews ZB, Foldi CJ.
bioRxiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyEating DisordersReceptor PharmacologyAnimal Study Animal Study

A Naturalistic Study on the Combined Neural and Psychological Effects of Psilocybin and Compassion Focused Imagery

Psilocybin is a classic psychedelic drug known to alter subjective experience and elicit long-term psychological changes, enhancing cognitive flexibility and reducing rigid self-related beliefs. Combined with compassion motivational primes that involve generating mental representations of compassion, it may increase the potential for activating the care-affi...

bioRxiv 2025-12-21 Pallavicini C, Llobenes L, Cavanna F, de la Fuente LA, Muller S, Costa M, Gumiy N, Bruno N, D’Amelio T, Basran J, Plowright P, Stolkiner A, Namías M, Gilbert P, Tagliazucchi E.
bioRxiv PREPRINT (not peer reviewed) psilocybin Brain ImagingDefault Mode NetworkAgingWellbeingPsychological FlexibilityDrug Interactions Other

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder.

Background and aimsThere is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative experiences of people participating in a study of psilocybin-assisted psychotherapy (PAT) to treat MA use disorder.Design and settingQualitative study of participants enrolled in a single arm, open-label pilot study of PAT ...

Unknown journal 2025-12-21 Brett J, Lea T, Knock E, Albert S, Acheson L, Siefried KJ, Job S.
Europe PMC Published psilocybin Spirituality Qualitative Study

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview.

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT) was launched in 2025 to address urgent gaps in supportive care for Canadians with cancer experiencing demoralization syndrome (loss of meaning, dysphoria, disheartenment, helplessness, a sense of failure) and related psychosocial distress. CAN-PACT has six major objectives: (1) to develo...

Current oncology (Toronto, Ont.) 2025-12-21 Carlson LE, Richardson H, Shore R, Albertyn CP, Balneaves LG, Bates A, Burnell M, Chochinov HM, Clements D, Deleemans J, Horlock H, Mathews J, McKenzie M, Savard C, Soares CN, Tu W, Williams M
PubMed Published psilocybin Clinical TrialRandomized Controlled TrialCancer PatientsHealthcare Workers Randomized Controlled Trial cancerclinical trials

Griffiths et al.'s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective.

Griffiths et al.'s recent "Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions" is an important study in the literature on psychedelic medicine and religious experience. In this commentary on the study, we argue: (1) The study design's implicit presupposition of perennialism in its conception ...

Unknown journal 2025-12-21 Lorenz J, Hawkins S, McCarthy B.
Europe PMC Published psilocybin SpiritualityMystical ExperienceSafety Other

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions.

BackgroundAlthough historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduri...

Unknown journal 2025-12-21 Griffiths RR, Jesse R, Richards WA, Johnson MW, Sepeda ND, Bossis AP, Ross S.
Europe PMC Published psilocybin WellbeingSpiritualitySafetyAdverse Events Clinical Trial

Live source coverage

3,983 indexed records across 8 active sources.

3,218Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.1%
  2. PubMed 303 records · 7.6%
  3. OpenAlex 288 records · 7.2%
  4. ClinicalTrials.gov 287 records · 7.2%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 159 records · 4%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.